Inhibition of Barrett's adenocarcinoma cell growth by simvastatin: involvement of Cox-2 and apoptosis-related proteins

Journal of Physiology and Pharmacology

Volumn 58, Issue SUPPL. 3, 2007, Pages 141-148

  Konturek, Peter C ^a   Burnat, G ^a   Hahn, E G ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Apoptosis; Barrett's adenocarcinoma; Bax; Bcl 2; Statins

Indexed keywords

BROMINE DERIVATIVE; CYCLOOXYGENASE 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ATTENUATION; BARRETT ESOPHAGUS; CARCINOGENESIS; CELL GROWTH; CONFERENCE PAPER; DOSE RESPONSE; DRUG DETERMINATION; DRUG EFFECT; DRUG INHIBITION; ESOPHAGEAL ADENOCARCINOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; ADENOCARCINOMA; ARTICLE; CELL PROLIFERATION; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; METABOLISM; PATHOPHYSIOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; BARRETT ESOPHAGUS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIMVASTATIN;

EID: 34948895062     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Jankowski JA HR, Perry I, Balkwill F, Tselepsis C. Barett's metaplasia. Lancet 2000; 356: 2079-2085.
2. Lagergren J BR, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831.
3. Wild CP HL: Reflux, Barett's esophagus and adenocarcinoma: burning questions. Nat Rev Cancer 2003; 3: 676-684.
4. Souza RF, Spechler SJ. Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin 2005; 55(6): 334-351.
5. Leedham S J, Jankowski J. The evidence base of proton pump inhibitor chemoprevative agents in Barett's esophagus - the good, the bad, and the flawed. Am J Gastroenterol 2007; 102(1): 21-23.
6. Vaughan TL, Dong LM, Blount PL et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's esophagus: a prospective study. Lancet Oncol 2005; 6(12): 945-952.
7. Bollschweiller E, Wolfgarten E, Nowroth T, Rosendahl U, Monig SP, Holscher AH. Vitamin intake and risk of subtypes of esophageal cancer in Germany. J Cancer Res Clin Oncol 2002; 128(10): 575-580.
8. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol 2004; 22(12): 2388-2394.
9. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003; 9(1): 10-19.
10. Buttar NS, Wang KK, Leontovich O et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002;122(4): 1101-1112.
11. Konturek PC, Nikiforuk A, Kania J, Raithel M, Hahn EG, Mühldorfer S. Activation of NFkappaB represents the central event in the neoplastic progression associated with Barett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors. Dig Dis Sci 2004; 49(7-8): 1075-1083.
12. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001; 96(4): 990-996.
13. Eksteen JA, Scott PA, Perry I, Jankowski JA. Inflammation promotes Barrett's metaplasia and cancer: a unique role for TNFalpha. Eur J Cancer Prev 2001; 10(2): 163-166.
14. Katada N, Hinder R, Smyrk TC et al. Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barett esophagus. Arch Surg 1997; 132(7): 728-733.
15. Dvorakova K, Payne CM, Ramsey L et al. Apoptosis resistance in Barrett's esophagus: ex vivo bioassay of live stressed tissues. Am J Gastroenterol 2005; 100(2): 424-431.
16. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26(9): 1324-1337.
17. Koyuturk M, Ersoz M, Altiok N. Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Cancer Lett 2007; 250(2): 220-228.
18. Sutter AP, Maaser K, Höpfner M, Huether A, Schuppan D, Scherübl H. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J Hepatol 2005; 43(5): 808-816.
19. Kalinowski L, Dobrycki IT, Maliński T Cerivastatin potentia nitric oxide release and eNOS expression through inhibition of isoprenoids synthesis. J Physiol Pharmacol 2002; 53: 585-595